American Bio Medica Corp

Market Cap $4.81K
Debt $350.00K
Cash $68.00K
EV $286.81K
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$850.00K
EBIT	$970.00K
ROA	147%
Equity	-$458.00K
Growth Stability	1
PE	0.01
PB	-0.01
P/S	0.01
Price/Cash	14.14
Debt/Equity	-0.76
Net Margins	1K%
Gross Margins	-20%
Op. Margins	134%
Sales Growth YoY	-53%
Sales Growth QoQ	-2%
Sales CAGR	-20%
FCF CAGR	-1%
Equity CAGR	-2%
Earnings Growth YoY	-596%

Earnings Growth QoQ	-693%
Sales CAGR 5Y	-26%
Earnings CAGR 3Y	-48%
Sales CAGR 3Y	-48%
Market Cap	$4.81K
Revenue	$726.00K
Assets	$659.00K
Total Debt	$350.00K
Cash	$68.00K
Shares Outstanding	48.1M
EV	286.81K
Working Capital	-458K
Current Ratio	0.59
Gross Profit	-$147.00K
Shares Growth 3y	-6%
Equity Growth QoQ	-80%
Equity Growth YoY	-65%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

American Bio Medica Corp is a US-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.

SEC Filings

Direct access to American Bio Medica Corp (ABMC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2023
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does American Bio Medica Corp compare to its competitors?

Not enough data to generate a comparison chart between American Bio Medica Corp and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of American Bio Medica Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

American Bio Medica Corp Discounted Cash Flow

Fully customizable DCF calculator online for American Bio Medica Corp.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	TTM
Net Margins	-7%	-5%	-6%	-11%	-27%	-19%	-19%	-21%	-154%	1K%
ROA	-	-3%	-2%	-9%	-30%	-20%	-32%	-14%	-98%	147%
ROE	-	-35%	-34%	-87%	704%	86%	63%	49%	60%	-

Good Net Margins (1.15K%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	TTM
Debt over FCF	-	13.04	10.28	15.04	-10.84	31.6	-5.11	-4.59	-	-
Debt over Equity	4.11	2.94	2.42	3.31	-16.34	-2.32	-1.98	-3.27	-1.91	-0.76
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.76)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	CAGR 5Y
Revenue YoY growth	-	-13%	-11%	-12%	-21%	-6%	13%	-47%	-59%	-26%
Earnings YoY growth	-	-32%	4%	58%	89%	-34%	17%	-42%	205%	-
Equity YoY growth	-	-1%	7%	-39%	-123%	441%	59%	-25%	148%	-
FCF YoY growth	-	362%	11%	-43%	-261%	-126%	-940%	38%	-	-